Stock Research: Co-Diagnostics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Co-Diagnostics

NasdaqCM:CODX US1897631057
14
  • Value
    80
  • Growth
    17
  • Safety
    Safety
    38
  • Combined
    38
  • Sentiment
    12
  • 360° View
    360° View
    14
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets diagnostics technologies for detecting and analyzing nucleic acid molecules. Its main businesses include PCR instruments and diagnostic test cup systems, with a focus on infectious disease applications and point-of-care/at-home use. In the last fiscal year, the company had a market cap of $9 million, profits of $3 million, revenue of $4 million, and 132 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 14 (better than 14% compared with alternatives), overall professional sentiment and financial characteristics for the stock Co-Diagnostics are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Co-Diagnostics. The only rank that is above average is the consolidated Safety Rank at 80, which means that the company has a financing structure that is safer than those of 80% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 38, which means that the share price of Co-Diagnostics is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 17, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 12, which means that professional investors are more pessimistic about the stock than for 88% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
38 41 38 77
Growth
17 13 1 43
Safety
Safety
80 80 55 55
Sentiment
12 4 9 16
360° View
360° View
14 14 1 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
12 7 1 50
Opinions Change
6 50 50 50
Pro Holdings
n/a 8 23 30
Market Pulse
23 15 19 7
Sentiment
12 4 9 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
38 41 38 77
Growth
17 13 1 43
Safety Safety
80 80 55 55
Combined
38 38 17 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
88 88 88 91
Price vs. Earnings (P/E)
1 5 15 62
Price vs. Book (P/B)
97 89 90 76
Dividend Yield
1 1 1 1
Value
38 41 38 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
5 3 4 6
Profit Growth
68 17 9 31
Capital Growth
51 54 37 99
Stock Returns
1 21 19 49
Growth
17 13 1 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
87 88 87 73
Liquidity
1 1 75 75
Safety Safety
80 80 55 55

Similar Stocks

Discover high‑ranked alternatives to Co-Diagnostics and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.